Bryan Dunyak
Director, Biomolecular Sciences & Lead Discovery Remix Therapeutics
Bryan Dunyak is Director of Biomolecular Sciences & Lead Discovery at Remix Therapeutics, where he drives early-stage discovery programs targeting RNA–protein complexes. A chemical biologist with more than a decade of multidisciplinary experience across academia and industry, Bryan specializes in biochemistry, biophysics, and translational discovery for protein conformational diseases and protein–protein interactions. He excels at leading interdisciplinary teams through hit-to-lead and lead optimisation. At the Summit, Bryan will share insights on adapting biophysics for the RNA–protein interface to tackle large, dynamic RNP assemblies in drug discovery.
Seminars
Thursday 30th April 2026
Adapting Biophysics for the RNA–Protein Interface to Tackle Large, Dynamic RNP Assemblies in Drug Discovery
12:00 pm
- Interrogate the unique structural and dynamic challenges of RNA–protein complexes, from disorder and charge density to multi-component assemblies with shifting stoichiometry
- Explore biophysical and biostructural methods adapted for RNP systems including strategies to minimize artefacts, probe conformational heterogeneity, and capture transient or cooperative interactions
- Discuss how hybrid approaches strengthen characterization of RNP behavior, revealing functional mechanisms and improving targetability for emerging therapeutic modalities
